Hidradenitis Suppurativa Market to Grow Positively at a Paltry CAGR During the Study Period, DelveInsight | Novartis Pharmaceuticals, UCB Biopharma, Incyte Corporation, AbbVie, Aclaris Therapeutics, Boehringer Ingelheim, UNION Therapeutics, ACELYRIN, Prio

DelveInsight's "Hidradenitis Suppurativa - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Hidradenitis Suppurativa market share of the individual therapies, current and forecasted Hidradenitis Suppurativa market size from 2020 to 2034 segmented by seven major markets. The report also offers current Hidradenitis Suppurativa therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Hidradenitis Suppurativa market.
Download our sample report @ https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Highlights from the Hidradenitis Suppurativa Market Report:
To highlight the market potential for hidradenitis suppurativa (HS), a condition affecting roughly 1% of the population, it is evident that with the right strategy, it could be highly lucrative. In 2023, the HS market across the 7MM was valued at nearly USD 1,400 million, with the largest share held by the US.
In the US, the highest number of HS cases in the 7MM was recorded at approximately 2,881,900 in 2023. Managing HS typically involves a multidisciplinary approach, including surgery, antibiotics (topical or systemic), corticosteroids, and procedural interventions like deroofing and excision. Biologics are crucial for moderate-to-severe cases and are transforming treatment strategies. Currently, HUMIRA (adalimumab) and COSENTYX (secukinumab) are FDA-approved for HS. BIMZELX (bimekizumab), approved in Europe, is under review by the US FDA, with a decision expected in April 2024.
HUMIRA, once a market leader, has seen its sales impacted by biosimilars launched in Europe and Japan in 2018 and 2021, and by AMJEVITA, the first HUMIRA biosimilar in the US, launched in January 2023. While COSENTYX, having the first-mover advantage, is seeing strong uptake, BIMZELX's effectiveness may pose a significant challenge due to its promising results compared to HUMIRA and COSENTYX.
The HS market is growing rapidly, driven by a diverse pipeline of new therapies targeting interleukins (e.g., IL-17, IL-36, IL-1a/b), PDE4 inhibitors, JAK inhibitors, and CXCR1/CXCR2 inhibitors. Investigational therapies for moderate-to-severe HS include Izokibep (ACELYRIN), Sonelokimab (MoonLake Immunotherapeutics), Povorcitinib (Incyte Corporation), Spesolimab (Boehringer Ingelheim), Lutikizumab (AbbVie), and Eltrekibart (Eli Lilly). Povrocitinib, in particular, may become the first oral medication in this growing market, with outcomes surpassing those of RINVOQ.
Noteworthy data presented at the American Academy of Dermatology 2024 conference include Incyte Corporation's Phase II study of ruxolitinib 1.5% cream and topline results from the Phase II MIRA trial evaluating Sonelokimab. Nanobodies, with their ability to target multiple pathways and superior tissue penetration, show significant promise for treating HS, with potential for Sonelokimab to rival COSENTYX if Phase III results align with Phase II findings.
Despite its impact on patients' well-being, the mild HS segment remains largely underserved, with only two emerging therapies-Orismilast and ruxolitinib cream-available.
Key hidradenitis suppurativa companies working in the hidradenitis suppurativa market are Novartis Pharmaceuticals, UCB Biopharma, Incyte Corporation, AbbVie, Aclaris Therapeutics, Boehringer Ingelheim, UNION Therapeutics, ACELYRIN, Priovant Therapeutics, MoonLake Immunotherapeutics, Eli Lilly, and others.

Hidradenitis Suppurativa Overview
Hidradenitis suppurativa (HS) is a chronic skin condition characterized by painful, swollen lesions primarily occurring in the armpits, groin, anal, and breast regions. It is marked by the formation of abscesses and scarring, and can progress from acute abscesses to a chronic state with persistent pain, sinus tract formation, and scarring. HS is often associated with depression and significantly impacts quality of life (QoL), surpassing other skin disorders in terms of QoL impairment, such as psoriasis, atopic dermatitis, alopecia, and acne.

The assessment of HS severity is conducted using various scoring systems, including Hurley staging, Physician's Global Assessment (PGA), the modified Sartorius score (MSS), and the Hidradenitis Suppurativa Severity Index (HSSI). The Hurley staging system categorizes the disease into three stages: Hurley stages 1, 2, and 3, reflecting the extent of the disease's spread.

Diagnosis of HS is primarily clinical, relying on the patient's symptoms and the physician's observations. There is no specific diagnostic test for HS, and biopsies are rarely needed, especially for well-developed lesions.

The primary treatment goals for HS are to alleviate lesion-related symptoms, reduce recurrence frequency, prevent new lesion formation, and halt disease progression and associated comorbidities.

First-line treatments for HS include topical clindamycin, oral clindamycin/rifampicin, tetracycline, and subcutaneous adalimumab. Second-line therapies encompass zinc gluconate, resorcinol, intralesional corticosteroids, infliximab, acitretin, and etretinate. Third-line treatments include colchicine, botulinum toxin, isotretinoin, dapsone, cyclosporine, and hormonal therapies. Surgical options include the excision of individual lesions, total excision of lesions surrounding hair-bearing skin, secondary intention healing, primary closure, reconstructive surgery with skin grafting and negative pressure wound therapy (NPWT) reconstruction with flap, deroofing, carbon dioxide laser therapy, laser therapy, and intense pulsed light treatments.

The preferred biologic agent for HS is HUMIRA (adalimumab), supported by extensive research. Other approved therapies include COSENTYX and BIMZELX for the treatment of moderate-to-severe HS in adults.

To know more about Hidradenitis Suppurativa, causes, signs and symptoms, diagnosis, treatment options, visit: https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hidradenitis Suppurativa Epidemiological Insights
In 2023, there were nearly 6.2 million prevalent cases of hidradenitis suppurativa (HS) across the 7MM, with this number expected to rise by 2034. The US reported the highest number of diagnosed HS cases in the 7MM, totaling approximately 877,600 in 2023.
Within the EU4 and the UK, Germany had the largest number of diagnosed HS cases, while Spain had the fewest. In the US, EU4, and the UK, HS was slightly more common in females (~75%) compared to males (~25%). In contrast, Japan showed a higher prevalence in males, who represented about 70% of cases, with females accounting for around 30%.
Age-specific data indicated that HS was most common in the 30-39 year age group, representing nearly 26% of all diagnosed cases in the US. Additionally, Hurley Stage I was the most prevalent stage in the US, with approximately 480,000 cases reported in 2023.

Hidradenitis Suppurativa Treatment Market
The mainstay of medical treatment of mild disease involves anti-bacterial washes and topical antibiotics. Acute flares may be managed by intralesional corticosteroids and/or minor surgical procedures. Oral therapies for mild to moderate HS include extended courses of broad-spectrum antibiotics and systemic retinoid. Currently, the market is mainly driven by off-label therapies and HUMIRA, as it is the only approved therapy for HS until now.
Promising Therapies in the Hidradenitis Suppurativa Pipeline
HUMIRA (adalimumab)
COSENTYX (secukinumab)
SKYRIZI (risankizumab)
BIMZELX (bimekizumab)
Bermekimab
OTEZLA (Apremilast)
And others
Discover more about Hidradenitis Suppurativa therapies in the pipeline @ https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Hidradenitis Suppurativa Market
Novartis Pharmaceuticals
UCB Biopharma
Incyte Corporation
AbbVie
Aclaris Therapeutics
Boehringer Ingelheim
UNION Therapeutics
ACELYRIN
Priovant Therapeutics
MoonLake Immunotherapeutics
Eli Lilly
And others
To understand key companies related to the Hidradenitis Suppurativa Market, get a snapshot of the Hidradenitis Suppurativa Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hidradenitis Suppurativa Market Outlook
Hidradenitis suppurativa (HS) is a chronic condition for which there is no cure, emphasizing the importance of early diagnosis and treatment to prevent worsening and additional scarring. The treatment strategies for HS are tailored based on the disease's severity and clinical staging.

Pharmacological Treatment Options

1. Topical and Systemic Antibiotics: These are commonly used for mild cases, including antibacterial washes and topical antibiotics.
2. Corticosteroids: Intralesional corticosteroids are used to manage acute flares.
3. Hormonal Therapy:
4. Systemic Retinoids:
5. Zinc Supplements:
6. Immunosuppressive Agents: This category includes biologics, which are increasingly used in more severe cases.

Marketed Therapies

- HUMIRA (adalimumab): Despite its patent expiring in December 2016 in the US, AbbVie's strong surrounding patents have maintained its market dominance until 2023.
- COSENTYX (secukinumab): Approved by the European Commission in June 2023 and later by the US FDA in October 2023 for moderate-to-severe HS in adults.
- BIMZELX (bimekizumab): Approved by the European Commission in April 2024 for the same indication.

Emerging Therapies

- Povorcitinib (INCB054707)
- Spesolimab (BI 655130)
- Lutikizumab
- Eltrekibart
- Orismilast
- Ruxolitinib Cream
- Izokibep
- Sonelokimab

The HS market is currently underserved, with a growing potential for multiple blockbuster medications, similar to the rheumatoid arthritis market. If the efficacy of oral drugs is comparable to subcutaneous injections, there may be a preference for oral therapies in this underappreciated market.

This overview highlights the evolving landscape of HS treatment, with a focus on both established and emerging therapies that aim to improve patient outcomes and quality of life.
Scope of the Hidradenitis Suppurativa Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Hidradenitis Suppurativa Companies: Novartis Pharmaceuticals, UCB Biopharma, Incyte Corporation, AbbVie, Aclaris Therapeutics, Boehringer Ingelheim, UNION Therapeutics, ACELYRIN, Priovant Therapeutics, MoonLake Immunotherapeutics, Eli Lilly, and others
Key Hidradenitis Suppurativa Pipeline Therapies: HUMIRA (adalimumab), COSENTYX (secukinumab), SKYRIZI (risankizumab), BIMZELX (bimekizumab), Bermekimab, OTEZLA (Apremilast), and others
Therapeutic Assessment: Hidradenitis Suppurativa current marketed and emerging therapies
Hidradenitis Suppurativa Market Dynamics: Hidradenitis Suppurativa market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Hidradenitis Suppurativa Market Access and Reimbursement
Table of Contents
1. Hidradenitis Suppurativa Market Key Insights
2. Hidradenitis Suppurativa Market Report Introduction
3. Hidradenitis Suppurativa Market Overview at a Glance
4. Hidradenitis Suppurativa Market Executive Summary
5. Disease Background and Overview
6. Hidradenitis Suppurativa Treatment and Management
7. Hidradenitis Suppurativa Epidemiology and Patient Population
8. Patient Journey
9. Hidradenitis Suppurativa Emerging Drugs
10. 7MM Hidradenitis Suppurativa Market Analysis
11. Hidradenitis Suppurativa Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Hidradenitis Suppurativa Market Drivers
15. Hidradenitis Suppurativa Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.